Febuxostat Patent Expiration
Febuxostat is Used for managing hyperuricemia in patients with gout. It was first introduced by Takeda Pharmaceuticals Usa Inc
Febuxostat Patents
Given below is the list of patents protecting Febuxostat, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Uloric | US8372872 | Methods for concomitant treatment of theophylline and febuxostat | Sep 08, 2031 | Takeda Pharms Usa |
| Uloric | US9107912 | Methods for concomitant treatment of theophylline and febuxostat | Sep 08, 2031 | Takeda Pharms Usa |
| Uloric | US7361676 | Solid preparation containing single crystal form |
Mar 08, 2024
(Expired) | Takeda Pharms Usa |
| Uloric | US6225474 | Polymorphs of 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazolecarboxylic acid and method of producing the same |
Jun 18, 2019
(Expired) | Takeda Pharms Usa |
| Uloric | US5614520 | 2-arylthiazole derivatives and pharmaceutical composition thereof |
Mar 25, 2019
(Expired) | Takeda Pharms Usa |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Febuxostat's patents.
Latest Legal Activities on Febuxostat's Patents
Given below is the list recent legal activities going on the following patents of Febuxostat.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 20 Feb, 2023 | US9107912 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 12 Aug, 2020 | US8372872 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 01 Oct, 2019 | US7361676(Litigated) |
| Payment of Maintenance Fee, 4th Year, Large Entity | 18 Feb, 2019 | US9107912 |
| Change in Power of Attorney (May Include Associate POA) Critical
| 30 Jan, 2019 | US9107912 |
| Email Notification Critical
| 30 Jan, 2019 | US9107912 |
| Correspondence Address Change Critical
| 29 Jan, 2019 | US9107912 |
| Change in Power of Attorney (May Include Associate POA) Critical
| 10 Sep, 2018 | US8372872 |
| Email Notification Critical
| 10 Sep, 2018 | US8372872 |
| Correspondence Address Change Critical
| 07 Sep, 2018 | US8372872 |
Febuxostat's Family Patents
